Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial

Chih Yuan Chung, Sheng Fung Lin, Po Min Chen, Ming Chih Chang, Woei You Kao, Tsu Yi Chao, Liang Tsai Hsiao, Chuen Chuan Yen, Muh Hwa Yang, Wei Shou Hwang, Tung Liang Lin, Tzeon Jye Chiou, Cheng Shyong Chang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS). Patients and Methods: Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP). Results: Thalidomide resulted in hematological improvement (HI) in 28% of ITT analysis and in HI in 40% of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7% for ITT and 10% for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients. Conclusion: Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.

Original languageEnglish
Pages (from-to)3415-3419
Number of pages5
JournalAnticancer Research
Volume32
Issue number8
Publication statusPublished - Aug 2012
Externally publishedYes

Fingerprint

Thalidomide
Myelodysplastic Syndromes
Taiwan
Therapeutics
Population
Intention to Treat Analysis
Fibroblast Growth Factor 2
Cytogenetics
Vascular Endothelial Growth Factor A
Bone Marrow
Cytokines

Keywords

  • Angiogenesis
  • Hematological improvement
  • Myelodysplastic syndromes
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chung, C. Y., Lin, S. F., Chen, P. M., Chang, M. C., Kao, W. Y., Chao, T. Y., ... Chang, C. S. (2012). Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial. Anticancer Research, 32(8), 3415-3419.

Thalidomide for the treatment of myelodysplastic syndrome in Taiwan : Results of a phase II trial. / Chung, Chih Yuan; Lin, Sheng Fung; Chen, Po Min; Chang, Ming Chih; Kao, Woei You; Chao, Tsu Yi; Hsiao, Liang Tsai; Yen, Chuen Chuan; Yang, Muh Hwa; Hwang, Wei Shou; Lin, Tung Liang; Chiou, Tzeon Jye; Chang, Cheng Shyong.

In: Anticancer Research, Vol. 32, No. 8, 08.2012, p. 3415-3419.

Research output: Contribution to journalArticle

Chung, CY, Lin, SF, Chen, PM, Chang, MC, Kao, WY, Chao, TY, Hsiao, LT, Yen, CC, Yang, MH, Hwang, WS, Lin, TL, Chiou, TJ & Chang, CS 2012, 'Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial', Anticancer Research, vol. 32, no. 8, pp. 3415-3419.
Chung, Chih Yuan ; Lin, Sheng Fung ; Chen, Po Min ; Chang, Ming Chih ; Kao, Woei You ; Chao, Tsu Yi ; Hsiao, Liang Tsai ; Yen, Chuen Chuan ; Yang, Muh Hwa ; Hwang, Wei Shou ; Lin, Tung Liang ; Chiou, Tzeon Jye ; Chang, Cheng Shyong. / Thalidomide for the treatment of myelodysplastic syndrome in Taiwan : Results of a phase II trial. In: Anticancer Research. 2012 ; Vol. 32, No. 8. pp. 3415-3419.
@article{3b1bfeb55ca24265a1167ae29810b096,
title = "Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial",
abstract = "Background: Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS). Patients and Methods: Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP). Results: Thalidomide resulted in hematological improvement (HI) in 28{\%} of ITT analysis and in HI in 40{\%} of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7{\%} for ITT and 10{\%} for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients. Conclusion: Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.",
keywords = "Angiogenesis, Hematological improvement, Myelodysplastic syndromes, Thalidomide",
author = "Chung, {Chih Yuan} and Lin, {Sheng Fung} and Chen, {Po Min} and Chang, {Ming Chih} and Kao, {Woei You} and Chao, {Tsu Yi} and Hsiao, {Liang Tsai} and Yen, {Chuen Chuan} and Yang, {Muh Hwa} and Hwang, {Wei Shou} and Lin, {Tung Liang} and Chiou, {Tzeon Jye} and Chang, {Cheng Shyong}",
year = "2012",
month = "8",
language = "English",
volume = "32",
pages = "3415--3419",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Thalidomide for the treatment of myelodysplastic syndrome in Taiwan

T2 - Results of a phase II trial

AU - Chung, Chih Yuan

AU - Lin, Sheng Fung

AU - Chen, Po Min

AU - Chang, Ming Chih

AU - Kao, Woei You

AU - Chao, Tsu Yi

AU - Hsiao, Liang Tsai

AU - Yen, Chuen Chuan

AU - Yang, Muh Hwa

AU - Hwang, Wei Shou

AU - Lin, Tung Liang

AU - Chiou, Tzeon Jye

AU - Chang, Cheng Shyong

PY - 2012/8

Y1 - 2012/8

N2 - Background: Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS). Patients and Methods: Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP). Results: Thalidomide resulted in hematological improvement (HI) in 28% of ITT analysis and in HI in 40% of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7% for ITT and 10% for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients. Conclusion: Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.

AB - Background: Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS). Patients and Methods: Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP). Results: Thalidomide resulted in hematological improvement (HI) in 28% of ITT analysis and in HI in 40% of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7% for ITT and 10% for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients. Conclusion: Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.

KW - Angiogenesis

KW - Hematological improvement

KW - Myelodysplastic syndromes

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84865685836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865685836&partnerID=8YFLogxK

M3 - Article

C2 - 22843924

AN - SCOPUS:84865685836

VL - 32

SP - 3415

EP - 3419

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -